Literature DB >> 29375229

Coexistence of Gitelman Syndrome and Hypertrophic Cardiomyopathy in a Pregnant Woman.

Abdullah Nabi Aslan1, Serkan Sivri1, Murat Can Güney2, Telat Keleş Prof2.   

Abstract

Gitelman syndrome (GS) is transmitted as an autosomal recessive trait and characterized by hypokalemic metabolic alkalosis in combination with significant hypomagnesemia and low urinary calcium excretion. The symptoms and severity of the disease can vary greatly from one person to another and can range from mild to severe. Sudden cardiac arrest has been reported occasionally as well. Here, for the first time, we reported a 34-year-old pregnant GS woman who was diagnosed to have hypertrophic obstructive cardiomyopathy during her cardiac examination for the complaints of palpitation and presyncope.

Entities:  

Keywords:  Gitelman syndrome; Hypertrophic cardiomyopathy; Pregnant; Sudden cardiac death

Year:  2018        PMID: 29375229      PMCID: PMC5777948          DOI: 10.6515/ACS.201801_34(1).20170515A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  11 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12       Impact factor: 5.209

2.  Gitelman's not-so-benign syndrome.

Authors:  Roman T Pachulski; Fernando Lopez; Rashid Sharaf
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

Review 3.  Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.

Authors:  J Martijn Bos; Jeffrey A Towbin; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2009-07-14       Impact factor: 24.094

4.  Cardiovascular events in pregnancy with hypertrophic cardiomyopathy.

Authors:  Hiroaki Tanaka; Chizuko Kamiya; Shinji Katsuragi; Kayo Tanaka; Takekazu Miyoshi; Mitsuhiro Tsuritani; Masashi Yoshida; Naoko Iwanaga; Reiko Neki; Jun Yoshimatsu; Tomoaki Ikeda
Journal:  Circ J       Date:  2014-08-06       Impact factor: 2.993

5.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

Authors:  B J Maron; J M Gardin; J M Flack; S S Gidding; T T Kurosaki; D E Bild
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

6.  Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter.

Authors:  D B Simon; C Nelson-Williams; M J Bia; D Ellison; F E Karet; A M Molina; I Vaara; F Iwata; H M Cushner; M Koolen; F J Gainza; H J Gitleman; R P Lifton
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

7.  Aborted sudden cardiac death in two patients with Bartter's/Gitelman's syndromes.

Authors:  R Scognamiglio; C Negut; L A Calò
Journal:  Clin Nephrol       Date:  2007-03       Impact factor: 0.975

8.  Electrocardiogram with prolonged QT interval in Gitelman disease.

Authors:  Alberto Bettinelli; Camillo Tosetto; Giacomo Colussi; Ginaluca Tommasini; Alberto Edefonti; Mario G Bianchetti
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

9.  Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome).

Authors:  Pietro E G Foglia; Alberto Bettinelli; Camillo Tosetto; Cinzia Cortesi; Laura Crosazzo; Alberto Edefonti; Mario G Bianchetti
Journal:  Nephrol Dial Transplant       Date:  2004-03-19       Impact factor: 5.992

Review 10.  Gitelman syndrome.

Authors:  Nine V A M Knoers; Elena N Levtchenko
Journal:  Orphanet J Rare Dis       Date:  2008-07-30       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.